• Millennium Pharmaceuticals Inc., of Cambridge, Mass., reported U.S. net sales of its multiple myeloma drug Velcade totaling $70.4 million for the third quarter, a 32 percent increase over the same period in 2006. That growth prompted the company to boost its financial guidance, which now projects U.S. Velcade sales to reach about $265 million in 2007. Royalties from sales of Velcade outside the U.S., where it is marketed by a unit of New Brunswick, N.J.-based Johnson & Johnson, rose 23 percent to $41.3 million. Millennium reported non-GAAP net income of $15.4 million for the three-month period. As of Sept. 30, the firm had $876.3 million in cash, cash equivalents and marketable securities. Shares of Millennium (NASDAQ:MLNM) closed Thursday at $11.72, down 10 cents.